drugset / Trial / NCT05932641
Study of AZD3152 Intramuscular Injection or Intravenous Infusion in Healthy Japanese Adult Participants
RandomizedParallel-groupQuadruple-blindPrevention
Summary
AZD3152 is being evaluated for administration to prevent COVID-19. This Phase I study will gather important information on the safety and tolerability of AZD3152 as well as relevant data on the PK, PD (as the neutralising responses against SARS-CoV-2) profile and the generation of ADA to AZD3152.
Timeline
- Start
- 2023-07-31
- Primary completion
- 2024-12-05
- Completion
- 2024-12-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sipavibart | Monoclonal antibody | 300 mg | Intramuscular |
| Subject | Sipavibart | Monoclonal antibody | 600 mg | Intramuscular |
| Subject | Sipavibart | Monoclonal antibody | 1200 mg | Intramuscular |